Targeting nanocomposites with anti-oxidative/inflammatory/angiogenic activities for synergistically alleviating macular degeneration
Source abstract
Abstract
Abstract Treatment of age-related macular degeneration (AMD) is a challenge due to frequent intravitreal injection of drugs, low retention time, risk of infection, need for drugs with multiple therapeutic efficacies, such as anti-inflammatory, anti-oxidant, and anti-angiogenesis. Herein, we demonstrate the synthesis and application of metformin-loaded gold-poly(catechin) core-shell nanoparticles (MF/Au@pCH NPs) as a potential nanocomposite for the treatment of AMD, via sustained drug release to the lesion site. To achieve targeted drug delivery to macula of the AMD eye, we immobilized the complement component protein C3 to form C3-MF/Au@pCH NPs. With this targeted nanocomposite, we aim to utilize the anti-oxidative and anti-inflammatory properties of phenol-rich poly(catechin) and the anti-angiogenic activity of metformin for the synergistic recovery from macular degeneration. The pharmacological efficacy of a single intravitreal dose of C3-MF/Au@pCH NPs is superior to Au@pCH NPs and MF/Au@pCH NPs. In addition, C3-MF/Au@pCH NPs exhibited good in vitro and in vivo biocompatibility. Our study suggests the potential of this multifunctional modality for translation into a clinical intervention for AMD therapy, due to the sustained release of drugs and targeted drug delivery. The findings of this work reveals that Au@pCH NPs could be extended to the treatment of various other diseases with the loading of relative drugs.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advanced Nanomaterials in Catalysis · Retinal Diseases and Treatments · Gold and Silver Nanoparticles Synthesis and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (96)
Show source-provided references
1. Age-related macular degeneration therapy: a review10.1097/ICU.0000000000000657 ↗
2. Age-related macular degeneration: new paradigms for treatment and management of AMD10.1155/2018/8374647 ↗
3. Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch's membrane/choriocapillaris complex10.1016/j.mam.2012.04.005 ↗
4. Central role of oxidative stress in age-related macular degeneration: evidence from a review of the molecular mechanisms and animal models10.1155/2020/7901270 ↗
5. Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group10.1016/j.ophtha.2019.11.004 ↗
6. Cellular and molecular mechanisms of age-related macular degeneration: from impaired autophagy to neovascularization10.1016/j.biocel.2013.04.013 ↗
7. Laser photocoagulation for neovascular age-related macular degeneration10.1002/14651858.CD004763.pub2 ↗
8. Consequences of oxidative stress in age-related macular degeneration10.1016/j.mam.2012.03.009 ↗
9. Autophagy dysfunction, cellular senescence, and abnormal immune-inflammatory responses in AMD: from mechanisms to therapeutic potential
10. How successful is switching from bevacizumab or ranibizumab to aflibercept in age-related macular degeneration? a systematic overview10.1007/s12325-019-00971-0 ↗
11. Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis10.1136/bjophthalmol-2018-312691 ↗
12. Inflammation and its role in age-related macular degeneration10.1007/s00018-016-2147-8 ↗
13. Metformin, a potential role in age-related macular degeneration: a systematic review and meta-analysis10.1007/s40123-021-00344-3 ↗
14. Metformin suppresses retinal angiogenesis and inflammation in vitro and in vivo
15. Nanodelivery of resveratrol-loaded PLGA nanoparticles for age-related macular degeneration10.1208/s12249-020-01836-4 ↗
16. Drug delivery techniques for treating age-related macular degeneration10.1517/17425247.2013.859135 ↗
17. Ranibizumab biosimilar/polyethyleneglycol-conjugated gold nanoparticles as a novel drug delivery platform for age-related macular degeneration10.1016/j.jddst.2017.01.004 ↗
18. Application of nanoparticles in ocular drug delivery systems10.1007/s12553-019-00381-w ↗
19. Nanotechnology-based strategies for treatment of ocular disease10.1016/j.apsb.2016.09.001 ↗
20. Nanotechnology: revolutionizing the delivery of drugs to treat age-related macular degeneration
21. Unique roles of gold nanoparticles in drug delivery, targeting and imaging applications10.3390/molecules22091445 ↗
22. The promising potentials of capped gold nanoparticles for drug delivery systems10.1080/1061186X.2017.1387790 ↗
23. Gold nanoparticles: emerging paradigm for targeted drug delivery system10.1016/j.biotechadv.2012.10.002 ↗
24. Antioxidant properties of catechins: comparison with other antioxidants10.1016/j.foodchem.2017.08.117 ↗
25. Metformin suppresses retinal angiogenesis and inflammation in vitro and in vivo
26. The effects of metformin on obesity-induced dysfunctional retinas10.1167/iovs.16-20691 ↗
27. Age related macular degeneration and drusen: neuroinflammation in the retina10.1016/j.pneurobio.2011.05.011 ↗
28. Johnson · Exp. Eye Res. · 2001 · 73 · 88710.1006/exer.2001.1094 ↗
29. Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases10.1038/s41433-020-0770-y ↗
30. Nanotechnology-based drug delivery treatments and specific targeting therapy for age-related macular degeneration10.1016/j.jcma.2015.07.008 ↗
31. Intravitreal anti-VEGF drug delivery systems for age-related macular degeneration10.1016/j.ijpharm.2019.118767 ↗
32. Therapeutic effects of a novel siRNA-based anti-VEGF (siVEGF) nanoball for the treatment of choroidal neovascularization10.1039/C7NR03142D ↗
33. Atorvastatin-loaded solid lipid nanoparticles as eye drops: proposed treatment option for age-related macular degeneration (AMD), Drug Deliv
34. Development of facile drug delivery platform of ranibizumab fabricated PLGA-pegylated magnetic nanoparticles for age-related macular degeneration therapy10.1016/j.jphotobiol.2018.04.033 ↗
35. Anti-VEGF-aptamer modified C-dots-a hybrid nanocomposite for topical treatment of ocular vascular disorders10.1002/smll.201902776 ↗
36. Glycol chitosan engineered autoregenerative antioxidant significantly attenuates pathological damages in models of age-related macular degeneration10.1021/acsnano.7b00429 ↗
37. Nanoceria-loaded injectable hydrogels for potential age-related macular degeneration treatment10.1002/jbm.a.36450 ↗
38. Light-Induced Nrf2−/− mice as atrophic age-related macular degeneration model and treatment with nanoceria laden injectable hydrogel10.1038/s41598-019-51151-7 ↗
39. Sustained protection against photoreceptor degeneration in tubby mice by intravitreal injection of nanoceria10.1016/j.biomaterials.2012.08.030 ↗
40. The role of oxidative stress and autophagy in blue-light-induced damage to the retinal pigment epithelium in zebrafish in vitro and in vivo10.3390/ijms22031338 ↗
41. Astrocyte hepcidin is a key factor in LPS-induced neuronal apoptosis10.1038/cddis.2017.93 ↗
42. Synergistically dual-functional nano eye-drops for simultaneous anti-inflammatory and anti-oxidative treatment of dry eye disease10.1039/C9NR00376B ↗
43. In situ formation of chiral core-shell nanostructures with raspberry-like gold cores and dense organic shells using catechin and their catalytic application10.1039/c2jm32303f ↗
44. Structure-activity relationships analysis of monomeric and polymeric polyphenols (quercetin, rutin and catechin) obtained by various polymerization methods
45. Surface plasmon resonance in gold nanoparticles: a review10.1088/1361-648X/aa60f3 ↗
46. Size-dependent surface plasmon resonance broadening in nonspherical nanoparticles: single gold nanorods10.1021/nl400777y ↗
47. Endothelial cell migration during angiogenesis10.1161/01.RES.0000259593.07661.1e ↗
48. Mechanotransduction in endothelial cell migration10.1002/jcb.20614 ↗
49. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases10.1093/jb/mvs136 ↗
50. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes10.2337/diabetes.51.7.2074 ↗
51. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD110.1158/0008-5472.CAN-10-1769 ↗
52. Metformin inhibits endothelial progenitor cell migration by decreasing matrix metalloproteinases, MMP-2 and MMP-9, via the AMPK/mTOR/autophagy pathway10.3892/ijmm.2017.2929 ↗
53. Effect of metformin on the proliferation, migration, and MMP-2 and -9 expression of human umbilical vein endothelial cells10.3892/mmr.2012.753 ↗
54. Metformin inhibits ALK1-mediated angiogenesis via activation of AMPK10.18632/oncotarget.15825 ↗
55. Smith · Cell · 2002 · 108 · 76910.1016/S0092-8674(02)00672-4 ↗
56. Polyphenol-mediated assembly of proteins for engineering functional materials10.1002/anie.202002089 ↗
57. Structure of gold nanoparticles suspended in water studied by x-ray diffraction and computer simulations10.1103/PhysRevB.72.195402 ↗
58. The cell biology of the retinal pigment epithelium10.1016/j.preteyeres.2020.100846 ↗
59. Autophagy and heterophagy dysregulation leads to retinal pigment epithelium dysfunction and development of age-related macular degeneration10.4161/auto.24546 ↗
60. Molecular mechanisms of retinal pigment epithelium damage and development of age-related macular degeneration10.1111/j.1755-3768.2011.02179.x ↗
61. Measurement of DNA damage with the comet assay in high-prevalence diseases: current status and future directions
62. DNA repair as a human biomonitoring tool: comet assay approaches10.1016/j.mrrev.2019.03.002 ↗
63. Matrix metalloproteinases and angiogenesis10.1111/j.1582-4934.2005.tb00355.x ↗
64. Role of matrix metalloproteinases in angiogenesis and cancer10.3389/fonc.2019.01370 ↗
65. Andrographolide inhibits human umbilical vein endothelial cell invasion and migration by regulating MMP-2 and MMP-9 during angiogenesis10.1615/JEnvironPatholToxicolOncol.v30.i1.40 ↗
66. Metformin treatment alleviates polycystic ovary syndrome by decreasing the expression of MMP-2 and MMP-9 via H19/miR-29b-3p and AKT/mTOR/autophagy signaling pathways10.1002/jcp.28594 ↗
67. Bakhashab · J. U. Weaver, Int. J. Mol. Sci · 2018 · 19 · 29310.3390/ijms19010293 ↗
68. Endothelial precursor cell migration during vasculogenesis10.1161/CIRCRESAHA.107.148932 ↗
69. The chick embryo chorioallantoic membrane as a model for in vivo research on angiogenesis10.1387/ijdb.9032025 ↗
70. The Folin-Ciocalteu assay revisited: improvement of its specificity for total phenolic content determination10.1039/c3ay41125g ↗
71. A microfluidic bioreactor with integrated transepithelial electrical resistance (TEER) measurement electrodes for evaluation of renal epithelial cells10.1002/bit.22835 ↗
72. Oxidative stress affects the junctional integrity of retinal pigment epithelial cells10.1167/iovs.03-0351 ↗
73. Signalling effects induced by acid ceramidase in human epithelial or leukemic cell lines10.33594/000000074 ↗
74. Tight junctions/adherens junctions: basic structure and function10.1038/sj.jid.5700865 ↗
75. The effect of tyrosine-specific protein-phosphorylation on the assembly of adherens-type junctions10.1002/j.1460-2075.1992.tb05225.x ↗
76. Parainflammation, chronic inflammation, and age-related macular degeneration10.1189/jlb.3RI0615-239R ↗
77. Catechin weakens diabetic retinopathy by inhibiting the expression of NF-κB signaling pathway-mediated inflammatory factors
78. Dietary polyphenols in age-related macular degeneration: protection against oxidative stress and beyond10.1155/2019/9682318 ↗
79. Epigallocatechin gallate (EGCG) prevents H2O2-induced oxidative stress in primary rat retinal pigment epithelial cells10.3109/02713683.2014.885532 ↗
80. Quercetin alleviates 4-hydroxynonenal-induced cytotoxicity and inflammation in ARPE-19 cells10.1016/j.exer.2015.02.001 ↗
81. IL-6 in inflammation, immunity, and disease, Cold Spring Harbor Perspect
82. Monocyte chemoattractant protein-1 (MCP-1): an overview10.1089/jir.2008.0027 ↗
83. Comprehensive expression patterns of inflammatory cytokines in aqueous humor of patients with neovascular age-related macular degeneration10.1038/s41598-019-55191-x ↗
84. Nepetin inhibits IL-1Β induced inflammation via NF-κB and MAPKs signaling pathways in ARPE-19 cells10.1016/j.biopha.2018.02.054 ↗
85. Animal models of age related macular degeneration10.1016/j.mam.2012.06.003 ↗
86. Exposure to excessive blue LED light damages retinal pigment epithelium and photoreceptors of pigmented mice10.1016/j.exer.2018.07.022 ↗
87. Mitochondria-derived reactive oxygen species mediate blue light-induced death of retinal pigment epithelial cells
88. Differentiating drusen: drusen and drusen-like appearances associated with ageing, age-related macular degeneration, inherited eye disease and other pathological processes10.1016/j.preteyeres.2016.04.008 ↗
89. Resveratrol as inducer of autophagy, pro-survival, and anti-inflammatory stimuli in cultured human RPE cells10.3390/ijms21030813 ↗
90. Mechanism of inflammation in age-related macular degeneration10.1155/2012/546786 ↗
91. Functional and morphological evaluation of blue light-emitting diode-induced retinal degeneration in mice10.1007/s00417-015-3258-x ↗
92. Chronic photo-oxidative stress and subsequent MCP-1 activation as causative factors for age-related macular degeneration
93. Animal models of ocular angiogenesis: from development to pathologies10.1096/fj.201700336R ↗
94. A quantitative and standardized method for the evaluation of choroidal neovascularization using MICRON III fluorescein angiograms in rats10.1371/journal.pone.0128418 ↗
95. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature10.1038/eye.2013.107 ↗
96. Oxidative stress and reactive oxygen species: a review of their role in ocular disease10.1042/CS20171246 ↗